Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction

Next Previous
Trial Profile

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 05 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glibenclamide (Primary) ; Alteplase
  • Indications Brain oedema; Cerebral infarction; Stroke
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms CHARM
  • Sponsors Biogen; Remedy Pharmaceuticals

Most Recent Events

  • 29 Jan 2025 According to a Remedy Pharmaceuticals media release, data from this study will be presented at the upcoming International Stroke Conference (ISC) being held February 5-7, 2025 at the Los Angeles Convention Center.
  • 01 Dec 2024 Results ( Between Aug 29, 2018, and May 23, 2023, n=535) assessing whether intravenous glibenclamide could improve functional outcome at 90 days in patients with large hemispheric infarction published in the Lancet Neurology
  • 01 Oct 2024 Results presented in a Remedy Pharmaceuticals Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top